FDA may inform its facility inspection decisions using data that would be provided by industry and combined into a publicly available index, thanks to a drug supply chain security provision in FDASIA.
FDA Could Release GMP Data To Prod Manufacturing Improvements
Batch failure and other measures commonly tracked by manufacturers could be aggregated into an industry-wide index that FDA would use to help make risk-based inspection decisions.